Verve Therapeutics Q2 2021 Earnings Report

Verve Therapeutics reported second quarter 2021 financial results and business highlights.

Key Takeaways

Verve Therapeutics reported a net loss of $53.0 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities were $417.6 million as of June 30, 2021, which includes net proceeds from Verve’s successful initial public offering.

Verve will present updated data from PCSK9 gene editing program and LNP delivery approach at TIDES 2021.

Verve published data demonstrating potent and durable lowering of PCSK9 in NHPs in Nature.

Verve completed a $306.7 million initial public offering in June 2021.

Verve expanded its board of directors to support future growth.

EPS

-$2.13

Previous year: -$0.26